These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard. Toh BT; Gregory SA; Knospe WH Am J Hematol; 1988 May; 28(1):58-60. PubMed ID: 3369437 [TBL] [Abstract][Full Text] [Related]
3. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918 [TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Tefferi A Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582 [TBL] [Abstract][Full Text] [Related]
5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S; Stock W; Godwin J; Fisher SG Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610 [TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054 [TBL] [Abstract][Full Text] [Related]
7. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691 [TBL] [Abstract][Full Text] [Related]
8. Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. Hirose Y; Masaki Y; Sugai S Eur J Haematol; 2002 Feb; 68(2):112-6. PubMed ID: 12061320 [TBL] [Abstract][Full Text] [Related]
9. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature. Shibata K; Shimamoto Y; Suga K; Sano M; Matsuzaki M; Yamaguchi M Acta Haematol; 1994; 91(2):84-8. PubMed ID: 8023650 [TBL] [Abstract][Full Text] [Related]
10. [Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7)]. Hayashi S; Iwama H; Uchida Y; Kawakubo K; Inatomi Y; Nagasu M; Miyazawa K; Ohyashiki JH; Ohyashiki K; Toyama K Rinsho Ketsueki; 1997 May; 38(5):445-7. PubMed ID: 9194391 [TBL] [Abstract][Full Text] [Related]
11. Essential thrombocythemia developing into refractory anemia and complicated by acute myeloid leukemia. Yonekura S; Nagao T; Arimori S Intern Med; 1992 Oct; 31(10):1224-7. PubMed ID: 1286233 [TBL] [Abstract][Full Text] [Related]
12. Essential thrombocythemia and acute leukemia. Ferrari D; Ticozzelli G; De Vizzi M; Corigliano P; De Vizzi G Haematologica; 1993; 78(6):401-2. PubMed ID: 8175035 [TBL] [Abstract][Full Text] [Related]
13. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Passamonti F; Lazzarino M Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648 [TBL] [Abstract][Full Text] [Related]
14. Is hydroxyurea leukemogenic in essential thrombocythemia? Tefferi A Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740 [No Abstract] [Full Text] [Related]
15. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Emilia G; Sacchi S; Temperani P; Longo R; Vecchi A Leuk Lymphoma; 1993 Mar; 9(4-5):423-6. PubMed ID: 8348078 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard. Hankins DG; Sanders S; MacDonald FM; Drage CW Chest; 1978 Mar; 73(3):415-6. PubMed ID: 272980 [TBL] [Abstract][Full Text] [Related]
17. [Essential thrombocythemia transformed to acute myeloblastic leukemia]. Okuda M; Shishido T; Sato A; Nagai T; Sugawara T; Kameoka J; Kaneda K; Meguro K; Fukuhara O; Sakurai T Rinsho Ketsueki; 1990 Oct; 31(10):1689-93. PubMed ID: 2255058 [TBL] [Abstract][Full Text] [Related]
18. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Björkholm M; Hultcrantz M; Derolf ÅR Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725 [TBL] [Abstract][Full Text] [Related]
19. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Randi ML; Fabris F; Girolami A Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989 [TBL] [Abstract][Full Text] [Related]
20. [Leukemic risk in thrombocythemia]. Liozon E; Turlure P Ann Med Interne (Paris); 1998 Mar; 149(2):82-6. PubMed ID: 11490529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]